摘要:
The present invention relates to a method of treatment and/or prophylaxis of a microbial infection, comprising the step of administering an effective amount of a compound of formula (I), in which X and Y are either the same or different and selected from a heteroatom; is a double or single bond depending on the heteroatoms X and Y; R 1 to R 5 are either the same or different and selected from hydrogen or a non-deleterious substituent; and R 6 and R 7 are either the same or different and selected from hydrogen and a non-deleterious substituent or one of R 6 and R 7 are absent when there is a double bond present, pharmaceutically acceptable salts or derivatives, pro-drugs, tautomers and/or isomers thereof. The present invention also relates to a method for protecting a subject from radiation damage, a method of cancer radiotherapy and use as an antimicrobial or radioprotective agent of the compound of formula (I) defined above. Some of the compounds of formula (I) are novel and are also described in the present invention, together with pharmaceutical or veterinary compositions containing them.
摘要:
The present invention relates to novel compounds of formula I wherein W, n, X and W' are defined in the description; invention compounds are modulators of metabotropic glutamate receptors - subtype 5 ("mGluR5") which are useful for the treatment of central nervous system disorders as well as other disorders modulated by mGluR5 receptors.
摘要:
Provided herein are compounds and methods of synthesis thereof. The compounds provided herein are useful for the treatment, prevention, and/or management of various disorders, such as neurological disorders, psychiatric disorders, neuromuscular disorders, gastrointestinal disorders, lower urinary tract disorder, and cancer. Compounds provided herein modulate the activity of metabotropic glutamate receptor 5 (mGluR5) in the central nervous system or the periphery. Pharmaceutical formulations containing the compounds and their methods of use are also provided herein.
摘要:
This invention relates to polymerizable ultraviolet light absorbers and yellow colorants and their use in ophthalmic lenses. In particular, this invention relates to polymerizable ultraviolet light absorbing methine compounds and yellow compounds of the methine and anthraquinone classes that block ultraviolet light and/or violet-blue light transmission through ophthalmic lenses.
摘要:
Disclosed is a compound which is useful as an endothelial lipase inhibitor. A pharmaceutical composition having inhibitory activity on endothelial lipase comprising a compound represented by the formula:
, its pharmaceutically acceptable salt, or a solvate thereof, wherein Ring A is nitrogen-containing hetero ring, Ring A may be substituted with a substituent other than a group represented by the formula: -C(R 1 R 2 )-C(=O)-NR 3 R 4 and a group represented by the formula: -R 5 , a broken line represents the presence or the absence of a bond, Z is -NR 6 -, =N-, -O-, or -S-, R 6 is halogen, substituted or unsubstituted alkyl or the like, R 1 and R 2 are each independently hydrogen, halogen, hydroxy, cyano, nitro, carboxy or substituted or unsubstituted alkyl, R 3 is hydrogen or substituted or unsubstituted alkyl, R 4 is hydrogen, substituted or unsubstituted alkyl or the like, R 3 and R 4 taken together with the adjacent nitrogen atom to which they are attached may form a substituted or unsubstituted ring, R 5 is hydrogen, halogen, hydroxy, cyano, nitro, carboxy, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl or the like.
摘要翻译:公开了可用作内皮脂肪酶抑制剂的化合物。 一种对内皮脂肪酶具有抑制活性的药物组合物,其含有下式所示化合物,其药学上可接受的盐或其溶剂化物,其中环A为含氮杂环,环A可以被除基团以外的取代基 由式-C(R 1 R 2)-C(= O)-NR 3 R 4表示的基团和由式-R 5表示的基团表示,虚线表示键的存在或不存在,Z是-NR 6 - ,= N -O-或-S-,R 6为卤素,取代或未取代的烷基等,R 1和R 2各自独立地为氢,卤素,羟基,氰基,硝基,羧基或取代或未取代的烷基,R 3为氢或 取代或未取代的烷基,R 4为氢,取代或未取代的烷基等,R 3和R 4与它们所连接的相邻氮原子一起可形成取代或未取代的环,R 5为氢,卤素,羟基,氰基, 硝基,羧基,取代的或未取代的 取代或未取代的烷基,取代或未取代的烯基,取代或未取代的炔基等。
摘要:
Substituted amides of the general formula (I): with the residues A, R 1 and R 2 as explained in detail in the description are described. The compounds are suitable in particular as neutral endopeptidase inhibitors and are highly potent.